← back to search

Marcel P. Trefny

LMU Klinikum ·
Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
h-index
17
citations
4,721
works
42
NIH funding
primary concept
Biology
email

Recent publications

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours
Nature Biomedical Engineering 2026cited by 2position: middledoi
Metabolites as agents and targets for cancer immunotherapy 
Nature Reviews Drug Discovery 2025cited by 17position: firstdoi
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma
Blood 2025cited by 9position: middledoi
Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy
Blood 2025cited by 0position: middledoi
Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies
Biological Chemistry 2024cited by 18position: middledoi
CAR T cells for solid tumors – developments to watch in 2023
Expert Opinion on Biological Therapy 2024cited by 3position: firstdoi
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer
Cell Reports Medicine 2023cited by 14position: middledoi
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Cell 2022cited by 252position: middledoi
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade
Science Translational Medicine 2022cited by 222position: middledoi
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
Nature Immunology 2020cited by 633position: middledoi
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Immunity 2018cited by 924position: middledoi
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Journal of Clinical Investigation 2018cited by 301position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Alfred Zippelius · University of Basel5 papers (2018–2023)Sebastian Kobold · German Center for Infection Research3 papers (2024–2025)Heinz Läubli · University of Basel2 papers (2018–2022)Michal A. Stanczak · Bloomberg (United States)2 papers (2018–2022)Camilla Jandus · University of Geneva1 papers (2020–2020)Christina Angeliki Tsiverioti · Ludwig-Maximilians-Universität München1 papers (2024–2024)Ira J. Goldberg · NYU Langone Health1 papers (2020–2020)Roy L. Silverstein · Medical College of Wisconsin1 papers (2020–2020)Ralph Weissleder · Harvard University1 papers (2018–2018)Zora Baumann · Novartis (Switzerland)1 papers (2023–2023)Ryoko Okamoto · ETH Zurich1 papers (2023–2023)Roberta Zappasodi · Cornell University1 papers (2020–2020) · 1 papers (2018–2018)Ana Luísa Correia · Disco (Germany)1 papers (2023–2023)Alain P. Algazi · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2018–2018)Fabien Franco · University of Lausanne1 papers (2020–2020)Laurence Zitvogel · Inserm1 papers (2025–2025)Guido Kroemer · Institut National du Cancer1 papers (2025–2025)Gordon J. Freeman · Harvard University1 papers (2018–2018) · 1 papers (2018–2018)